SCHEMBL16933512

SCHEMBL16933512

COCCOCc1ccc(-c2ccc(C3(NC(=O)N[C@@]4(C)CN5CCC4CC5)CC3)cc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 6/20 0.38
▸ CHRNA7 P36544 1/20 0.34
▸ OPRM1 P35372 1/20 0.33
▸ OPRL1 P41146 1/20 0.33
▸ MCHR1 Q99705 1/20 0.33
▸ DRD2 P14416 4/20 0.32
▸ DRD4 P21917 4/20 0.32
▸ DRD3 P35462 4/20 0.32
▸ KRAS P01116 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16933513 1.00 HRH3 (0.38) HRH3CHRNA7OPRM1OPRL1MCHR1
SCHEMBL16934033 1.00 HRH3 (0.38) HRH3CHRNA7OPRM1OPRL1MCHR1
SCHEMBL16933500 0.93 HRH3 (0.38) HRH3CHRNA7OPRM1OPRL1MCHR1
SCHEMBL15578170 0.88 HRH3 (0.42) HRH3CHRNA7MCHR1
SCHEMBL15579258 0.87 HRH3 (0.37) HRH3CHRNA7OPRM1OPRL1MCHR1
SCHEMBL15578183 0.87 PTGER4 (0.37) HRH3
SCHEMBL15578179 0.84 HRH3 (0.38) HRH3
SCHEMBL15579379 0.84 HRH3 (0.33) HRH3MCHR1DRD2DRD4DRD3
SCHEMBL15577988 0.80 HRH3 (0.42) HRH3CHRNA7MCHR1
SCHEMBL12614203 0.80 MCHR1 (0.39) MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2025-01-23 — — US disclosed
US-12060349-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2024-08-13 — — US disclosed
EP-4098654-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS Genzyme Corporation (US) 2022-12-07 — — EP disclosed
CN-114533729-A Glucosylceramide synthase inhibitors 建新公司 2022-05-27 — — CN disclosed
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2022-03-10 — — US disclosed
EP-2895484-B1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORP (US) 2022-02-23 — — EP disclosed
CN-108864076-B Glucosylceramide synthase inhibitors 建新公司 2022-02-11 — — CN disclosed
US-11008316-B2 Glucosylceramide synthase inhibitors GENZYME CORPORATION (US) 2021-05-18 — — US disclosed
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2018-03-08 — — US disclosed
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2015-07-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210681-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885OPRM1 4772/4885
US-20180065957-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885OPRM1 4772/4885
US-11008316-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GAA HRH3 3913/4885CHRNA7 4652/4885OPRM1 4760/4885
US-12060349-B2 Glucosylceramide synthase inhibitors GBA1, GBA2, GALC HRH3 4106/4885CHRNA7 4254/4885OPRM1 4766/4885
US-20250026749-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885OPRM1 4772/4885
US-20220073508-A1 GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GBA1, GBA2, GAA HRH3 3525/4885CHRNA7 4631/4885OPRM1 4772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback